{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:41:44Z","timestamp":1775886104432,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12967-015-0682-y","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T19:37:19Z","timestamp":1444073839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis"],"prefix":"10.1186","volume":"13","author":[{"given":"Daniel","family":"Pineda-Tenor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda A.","family":"Jim\u00e9nez-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"V\u00e1zquez-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-0450","authenticated-orcid":false,"given":"Salvador","family":"Resino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"issue":"12","key":"682_CR1","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/apt.12764","volume":"39","author":"MH Miller","year":"2014","unstructured":"Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, et al. Review article: 2014 UK consensus guidelines\u2014hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2014;39(12):1363\u201375.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"682_CR2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA","year":"2015","unstructured":"AASLD\/IDSA. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932\u201354.","journal-title":"Hepatology."},{"key":"682_CR3","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","DOI":"10.1016\/j.jhep.2013.11.003"},{"issue":"11","key":"682_CR4","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2014.11373","volume":"312","author":"BM Kuehn","year":"2014","unstructured":"Kuehn BM. Guideline: new HCV drugs should go to sickest patients. JAMA. 2014;312(11):1084\u20135.","journal-title":"JAMA"},{"issue":"2","key":"682_CR5","doi-asserted-by":"crossref","first-page":"e1001072","DOI":"10.1371\/journal.pcbi.1001072","volume":"7","author":"SM Krishnan","year":"2011","unstructured":"Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol. 2011;7(2):e1001072.","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"682_CR6","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/j.gastro.2010.12.038","volume":"140","author":"Y Hitomi","year":"2011","unstructured":"Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology. 2011;140(4):1314\u201321.","journal-title":"Gastroenterology"},{"issue":"4","key":"682_CR7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","volume":"31","author":"L Franceschi De","year":"2000","unstructured":"De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31(4):997\u20131004.","journal-title":"Hepatology"},{"issue":"7287","key":"682_CR8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature08825","volume":"464","author":"J Fellay","year":"2010","unstructured":"Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405\u20138.","journal-title":"Nature"},{"issue":"6","key":"682_CR9","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/hep.27022","volume":"59","author":"JA Holmes","year":"2014","unstructured":"Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology. 2014;59(6):2152\u201360.","journal-title":"Hepatology"},{"key":"682_CR10","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139(4):1181\u20131189.e1182.","DOI":"10.1053\/j.gastro.2010.06.016"},{"issue":"2","key":"682_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1373\/clinchem.2005.059501","volume":"52","author":"M Shipkova","year":"2006","unstructured":"Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006;52(2):240\u20137.","journal-title":"Clin Chem"},{"issue":"4\u20135","key":"682_CR12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00439-002-0798-z","volume":"111","author":"S Sumi","year":"2002","unstructured":"Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, Thein SL, Ansari A, Sanderson J, De Abreu RA, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111(4\u20135):360\u20137.","journal-title":"Hum Genet"},{"issue":"2","key":"682_CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2753.2001.00281.x","volume":"7","author":"AJ Sutton","year":"2001","unstructured":"Sutton AJ, Abrams KR, Jones DR. An illustrated guide to the methods of meta-analysis. J Eval Clin Pract. 2001;7(2):135\u201348.","journal-title":"J Eval Clin Pract"},{"issue":"7","key":"682_CR14","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"11","key":"682_CR15","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1872-034X.2010.00741.x","volume":"40","author":"N Sakamoto","year":"2010","unstructured":"Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, et al. ITPA gene variant protects against anemia induced by pegylated interferon-\u03b1 and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010;40(11):1063\u201371.","journal-title":"Hepatol Res"},{"issue":"2","key":"682_CR16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.24068","volume":"53","author":"AJ Thompson","year":"2011","unstructured":"Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2\/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011;53(2):389\u201395.","journal-title":"Hepatology"},{"issue":"6","key":"682_CR17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/jmv.22069","volume":"83","author":"T Azakami","year":"2011","unstructured":"Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, et al. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011;83(6):1048\u201357.","journal-title":"J Med Virol"},{"issue":"5","key":"682_CR18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3851\/IMP1796","volume":"16","author":"M Kurosaki","year":"2011","unstructured":"Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther. 2011;16(5):685\u201394.","journal-title":"Antivir Ther"},{"issue":"12","key":"682_CR19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/cid\/cir665","volume":"53","author":"NI Rall\u00f3n","year":"2011","unstructured":"Rall\u00f3n NI, Morello J, Labarga P, Benito JM, Rodr\u00edguez-N\u00f3voa S, Vispo E, Barreiro P, Castro M\u00c1, Aguirrebengoa K, Pineda JA, et al. Impact of inosine triphosphatase gene variants on the risk of anemia in HIV\/hepatitis C virus-coinfected patients treated for chronic hepatitis C. Clin Infect Dis. 2011;53(12):1291\u20135.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"682_CR20","first-page":"517","volume":"5","author":"T Nishimura","year":"2012","unstructured":"Nishimura T, Osaki R, Shioya M, Imaeda H, Aomatsu T, Takeuchi T, Okumura Y, Fujiyama Y, Andoh A. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients. Mol Med Rep. 2012;5(2):517\u201320.","journal-title":"Mol Med Rep"},{"issue":"3","key":"682_CR21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/infdis\/jir754","volume":"205","author":"S Naggie","year":"2012","unstructured":"Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV\/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012;205(3):376\u201383.","journal-title":"J Infect Dis"},{"issue":"6","key":"682_CR22","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1128\/AAC.06473-11","volume":"56","author":"P Domingo","year":"2012","unstructured":"Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J, et al. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV\/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012;56(6):2987\u201393.","journal-title":"Antimicrob Agents Chemother."},{"issue":"7","key":"682_CR23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/jmv.23302","volume":"84","author":"A Osinusi","year":"2012","unstructured":"Osinusi A, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, et al. ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. J Med Virol. 2012;84(7):1106\u201314.","journal-title":"J Med Virol"},{"issue":"41","key":"682_CR24","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v18.i41.5879","volume":"18","author":"A Tsubota","year":"2012","unstructured":"Tsubota A, Shimada N, Abe H, Yoshizawa K, Agata R, Yumoto Y, Ika M, Namiki Y, Nagatsuma K, Matsudaira H, et al. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C. World J Gastroenterol. 2012;18(41):5879\u201388.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"682_CR25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2012.11.027","volume":"58","author":"M Rau","year":"2013","unstructured":"Rau M, Stickel F, Russmann S, Manser CN, Becker PP, Weisskopf M, Schmitt J, Dill MT, Dufour J-F, Moradpour D, et al. Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. J Hepatol. 2013;58(4):669\u201375.","journal-title":"J Hepatol"},{"issue":"2","key":"682_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2893.2012.01637.x","volume":"20","author":"V Marco Di","year":"2013","unstructured":"Di Marco V, Calvaruso V, Grimaudo S, Ferraro D, Pipitone RM, Di Stefano R, Crax\u00ec A. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. J Viral Hepat. 2013;20(2):113\u201321.","journal-title":"J Viral Hepat"},{"issue":"9","key":"682_CR27","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3748\/wjg.v19.i9.1387","volume":"19","author":"WH Ahmed","year":"2013","unstructured":"Ahmed WH, Furusyo N, Zaky S, Eldin AS, Aboalam H, Ogawa E, Murata M, Hayashi J. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World J Gastroenterol. 2013;19(9):1387\u201395.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"682_CR28","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jhep.2013.06.030","volume":"59","author":"T-M Scherzer","year":"2013","unstructured":"Scherzer T-M, St\u00e4ttermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, et al. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol. 2013;59(5):964\u201371.","journal-title":"J Hepatol"},{"issue":"1","key":"682_CR29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.antiviral.2013.07.021","volume":"100","author":"A D\u2019Avolio","year":"2013","unstructured":"D\u2019Avolio A, De Nicol\u00f2 A, Cusato J, Ciancio A, Boglione L, Strona S, Cariti G, Troshina G, Caviglia GP, Smedile A, et al. Association of ITPA polymorphisms rs6051702\/rs1127354 instead of rs7270101\/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. Antiviral Res. 2013;100(1):114\u20139.","journal-title":"Antiviral Res"},{"issue":"12","key":"682_CR30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/jvh.12113","volume":"20","author":"PJ Clark","year":"2013","unstructured":"Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D\u2019Ambrosio R, et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat. 2013;20(12):858\u201366.","journal-title":"J Viral Hepat"},{"issue":"7","key":"682_CR31","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/jvh.12171","volume":"21","author":"K Matsuura","year":"2014","unstructured":"Matsuura K, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, et al. ITPA genetic variants influence efficacy of PEG-IFN\/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type. J Viral Hepat. 2014;21(7):466\u201374.","journal-title":"J Viral Hepat"},{"issue":"2","key":"682_CR32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.5009\/gnl14095","volume":"9","author":"JJ Hwang","year":"2015","unstructured":"Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver. 2015;9(2):214\u201323.","journal-title":"Gut Liver"},{"issue":"11","key":"682_CR33","doi-asserted-by":"crossref","first-page":"e47725","DOI":"10.1371\/journal.pone.0047725","volume":"7","author":"F Vidal","year":"2012","unstructured":"Vidal F, L\u00f3pez-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, Gallart L, Auguet T, Samp\u00e9riz G, et al. Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. PLoS One. 2012;7(11):e47725.","journal-title":"PLoS One"},{"issue":"4","key":"682_CR34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2013.05.017","volume":"59","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol. 2013;59(4):667\u201374.","journal-title":"J Hepatol"},{"issue":"4","key":"682_CR35","doi-asserted-by":"crossref","first-page":"e95881","DOI":"10.1371\/journal.pone.0095881","volume":"9","author":"A Aghemo","year":"2014","unstructured":"Aghemo A, Grassi E, Rumi MG, D\u2019Ambrosio R, Galmozzi E, Degasperi E, Castaldi D, Soffredini R, Colombo M. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PLoS One. 2014;9(4):e95881.","journal-title":"PLoS One"},{"issue":"1","key":"682_CR36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jir210","volume":"204","author":"K Chayama","year":"2011","unstructured":"Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84\u201393.","journal-title":"J Infect Dis"},{"issue":"8","key":"682_CR37","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3390\/v4081264","volume":"4","author":"T Miyamura","year":"2012","unstructured":"Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, Yokosuka O. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses. 2012;4(8):1264\u201378.","journal-title":"Viruses"},{"issue":"3","key":"682_CR38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4292\/wjgpt.v4.i3.54","volume":"4","author":"T Fujino","year":"2013","unstructured":"Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, et al. Association of ITPA polymorphism with outcomes of peginterferon-alpha plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther. 2013;4(3):54\u201360.","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"7","key":"682_CR39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/jvh.12047","volume":"20","author":"WK Seto","year":"2013","unstructured":"Seto WK, Tsang OTY, Liu K, Chan JMC, Wong DKH, Fung J, Lai CL, Yuen MF. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. J Viral Hepat. 2013;20(7):470\u20137.","journal-title":"J Viral Hepat"},{"issue":"3","key":"682_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11604-012-0163-7","volume":"31","author":"M Nakagawa","year":"2013","unstructured":"Nakagawa M, Hara M, Shibamoto Y. MRI findings in fetuses with an abdominal wall defect: gastroschisis, omphalocele, and cloacal exstrophy. Jpn J Radiol. 2013;31(3):153\u20139.","journal-title":"Jpn J Radiol"},{"issue":"6","key":"682_CR41","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/hep.27009","volume":"59","author":"K Rembeck","year":"2014","unstructured":"Rembeck K, Waldenstr\u00f6m J, Hellstrand K, Nilsson S, Nystr\u00f6m K, Martner A, Lindh M, Norkrans G, Westin J, Pedersen C, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2\/3. Hepatology. 2014;59(6):2131\u20139.","journal-title":"Hepatology"},{"issue":"11","key":"682_CR42","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1440-1746.2004.03459.x","volume":"19","author":"H Nomura","year":"2004","unstructured":"Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, Nagano M, Higashi M, Mukai T, Matsui Y, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol. 2004;19(11):1312\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"682_CR43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00535-003-1363-9","volume":"39","author":"S Takaki","year":"2004","unstructured":"Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, Suzuki F, Suzuki Y, Saitoh S, Arase Y, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39(7):668\u201373.","journal-title":"J Gastroenterol"},{"issue":"6","key":"682_CR44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0168-8278(01)00029-0","volume":"34","author":"H Vlierbergh Van","year":"2001","unstructured":"Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. J Hepatol. 2001;34(6):911\u20136.","journal-title":"J Hepatol"},{"issue":"10","key":"682_CR45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10038-004-0183-y","volume":"49","author":"S Marsh","year":"2004","unstructured":"Marsh S, King CR, Ahluwalia R, McLeod HL. Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet. 2004;49(10):579\u201381.","journal-title":"J Hum Genet"},{"issue":"4","key":"682_CR46","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","volume":"139","author":"H Ochi","year":"2010","unstructured":"Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy\u2014a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139(4):1190\u20137.","journal-title":"Gastroenterology"},{"issue":"11","key":"682_CR47","first-page":"2491","volume":"98","author":"DT Dieterich","year":"2003","unstructured":"Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98(11):2491\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"682_CR48","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s00535-012-0579-y","volume":"47","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol. 2012;47(11):1228\u201337.","journal-title":"J Gastroenterol"},{"issue":"2","key":"682_CR49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"Liver EAftSot","year":"2014","unstructured":"Liver EAftSot. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392\u2013420.","journal-title":"J Hepatol."},{"issue":"4","key":"682_CR50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/jvh.12346","volume":"22","author":"MP Manns","year":"2015","unstructured":"Manns MP, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, et al. Simeprevir with peginterferon\/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepat. 2015;22(4):366\u201375.","journal-title":"J Viral Hepat"},{"issue":"3","key":"682_CR51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.27567","volume":"61","author":"E Lawitz","year":"2015","unstructured":"Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12\u00a0weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769\u201375.","journal-title":"Hepatology"},{"issue":"6","key":"682_CR52","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","volume":"61","author":"S Pungpapong","year":"2015","unstructured":"Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880\u20136.","journal-title":"Hepatology"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0682-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T03:27:40Z","timestamp":1567222060000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.translational-medicine.com\/content\/13\/1\/320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/s12967-015-0682-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]},"article-number":"320"}}